For years, medical treatments for obesity and type 2 diabetes have focused on the brain and gut. Drugs in the glucagon like ...

Researchers have developed a new oral drug that boosts metabolic activity in muscle rather than altering appetite like GLP-1 ...

Sciele Pharma, Inc., of Atlanta and Novo Nordisk Inc., of Denmark, have announced approval for PrandiMet (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the ...

Young adults are increasingly facing type 2 diabetes risk due to stress and unhealthy habits, even if they appear thin. Doctor highlights this alarmin ...

The combination of empagliflozin and linagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Shares of Zydus Lifesciences Ltd ended at ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight loss.

Zydus Lifesciences is set to be in focus after it received tentative approval from the United States Food and Drug Administration for Empagliflozin and Linagliptin combination tablets for type 2 ...

In a new paper published in Clinical Nutrition, "Sarcopenic Diabetes Is an Under-Recognized and Unmet Clinical Priority," ...

A recent Cleveland Clinic study used AI to create digital twins of patients' metabolisms—and cured 7 in 10 type 2 diabetics.

In the U.S., both Jardiance and Tradjenta are once-daily tablets used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. Jardiance is also approved to reduce the risk of ...

Lowering blood sugar and increasing fat burning without reducing appetite or muscle mass is emerging as a promising ...